5-(4-fluorobenzyl)-3-hydroxymethylpyridine-2-carboxylic acid isopropyl ester | 862508-86-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 5-(4-fluorobenzyl)-3-hydroxymethylpyridine-2-carboxylic acid isopropyl ester
• 英文别名: propan-2-yl 5-[(4-fluorophenyl)methyl]-3-(hydroxymethyl)pyridine-2-carboxylate
• CAS: 862508-86-9
• 化学式: C₁₇H₁₈FNO₃
• 分子量: 303.333
• InChiKey: HRKGNASNRQFGFR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  22
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  59.4
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  5-(4-fluorobenzyl)-3-hydroxymethylpyridine-2-carboxylic acid isopropyl ester 、 对甲苯磺酰甘氨酸甲酯 在 sodium methylate 作用下， 以83%的产率得到3-(4-fluorobenzyl)-8-hydroxy-1,6-naphthyridine-7-carboxylic acid methyl ester
  参考文献：
  名称：

  EP1714966

  摘要：

  公开号：

文献信息

• Naphthyridine derivatives having inhibitory activity against hiv integrase
  申请人：Taishi Teruhiko

  公开号：US20090227621A1

  公开（公告）日：2009-09-10

  [Problems to be Solved] To provide a novel compound having antiviral activity, especially inhibitory activity against HIV integrase, a pharmaceutical composition, especially anti-HIV drug, containing the same. [Means to Solve the Problem] A compound of the formula: (wherein: R 1 is optionally substituted aralkyl; R 2 and R 3 are each independently hydrogen, optionally substituted alkyl, optionally substituted amino, optionally substituted alkenyl or optionally substituted alkoxy (provided that each substituent for “optionally substituted” is a noncyclic group); R 4 is hydrogen, optionally substituted carboxy, optionally substituted formylamino, optionally substituted carbamoyl, optionally substituted amino (provided that a substituent on amino in “optionally substituted formylamino”, “optionally substituted carbamoyl” and “optionally substituted amino” may form an optionally-substituted N-atom containing heterocyclic ring together with an adjacent N atom), optionally substituted alkyl, optionally substituted alkenyl, optionally substituted aryl, or optionally substituted heteroaryl) or a salt thereof.

  【需要解决的问题】提供一种具有抗病毒活性，特别是对HIV整合酶具有抑制活性的新型化合物，以及包含该化合物的制药组合物，特别是抗HIV药物。 【解决问题的方法】 化合物的化学式为：（其中：R1是可选取代的芳基甲基；R2和R3分别是氢、可选取代的烷基、可选取代的氨基、可选取代的烯基或可选取代的烷氧基（提供“可选取代”中的每个取代基均为非环状基）；R4是氢、可选取代的羧基、可选取代的甲酰胺基、可选取代的氨基甲酰胺基、可选取代的氨基（在“可选取代的甲酰胺基”、“可选取代的氨基甲酰胺基”和“可选取代的氨基”中，氨基上的取代基可以与相邻的N原子一起形成一个含有可选取代的N原子的杂环环），可选取代的烷基、可选取代的烯基、可选取代的芳基或可选取代的杂环芳基）或其盐。
• Heterocyclic compounds having inhibitory activity against HIV integrase
  申请人：Murai Hitoshi

  公开号：US20090118233A1

  公开（公告）日：2009-05-07

  A heterocyclic compound of the formula (I): wherein B 1 is —C(R 2 )═ or —N═; R 1′ is H, etc.; one of R 1 and R 2 is -Z 1 -Z 2 -Z 3 -R 5 wherein Z 1 and Z 3 are independently single bond, optionally substituted alkylene, etc.; Z 2 is single bond, optionally substituted alkylene, etc.; R 5 is optionally substituted aryl, optionally substituted heteroaryl, etc., and the other of R 1 and R 2 is H; -A 1 - is —C(—Y)═C(—R A )—C(—R 3 )═C(—R 4 )—, etc. wherein Y is OH, etc.; R A is —COR 7 wherein R 7 is OH, etc.; one of R 3 and R 4 is carboxy, etc., and the other of R 1 and R 2 is H, etc, a prodrug thereof, a pharmaceutically acceptable salt thereof, and a solvate thereof, having an antiviral activity, more particularly, an inhibitory activity against HIV integrase, and a pharmaceutical composition containing the same, especially an anti-HIV drug.

  一种具有以下式（I）的杂环化合物：其中B1为—C（R2）═或—N═；R1'为H等；R1和R2中的一个为-Z1-Z2-Z3-R5，其中Z1和Z3分别为单键，可选择性地取代的烷基等；Z2为单键，可选择性地取代的烷基等；R5为可选择性取代的芳基，可选择性取代的杂环芳基等；R1和R2中的另一个为H；-A1-为—C（—Y）═C（—RA）—C（—R3）═C（—R4）—等，其中Y为OH等；RA为—COR7，其中R7为OH等；R3和R4中的一个为羧基等，另一个为H等。该化合物的前药、其药学上可接受的盐和溶剂化物具有抗病毒活性，尤其是对HIV整合酶的抑制活性，并且包含该化合物的药物组合物，特别是一种抗HIV药物。
• Naphthyridine derivatives having inhibitory activity against HIV integrase
  申请人：Shionogi & Co., Ltd.

  公开号：US07919623B2

  公开（公告）日：2011-04-05

  A compound having HIV Integrase Inhibitory activity of the formula: (wherein: R1 is optionally substituted aralkyl; R2 and R3 are each independently hydrogen, optionally substituted alkyl, optionally substituted amino, optionally substituted alkenyl or optionally substituted alkoxy (provided that each substituent for “optionally substituted” is a noncyclic group); R4 is hydrogen, optionally substituted carboxy, optionally substituted formylamino, optionally substituted carbamoyl, optionally substituted amino (provided that a substituent on amino in “optionally substituted formylamino”, “optionally substituted carbamoyl” and “optionally substituted amino” may form an optionally-substituted N-atom containing heterocyclic ring together with an adjacent N atom), optionally substituted alkyl, optionally substituted alkenyl, optionally substituted aryl, or optionally substituted heteroaryl) or a salt thereof.

  一种具有HIV整合酶抑制活性的化合物的化学式为：（其中：R1是可选择取代的芳基甲基；R2和R3各自独立地为氢、可选择取代的烷基、可选择取代的氨基、可选择取代的烯基或可选择取代的烷氧基（前提是“可选择取代”的每个取代基都是非环状基）；R4为氢、可选择取代的羧基、可选择取代的甲酰胺基、可选择取代的氨基甲酰胺基、可选择取代的氨基（前提是“可选择取代”的“甲酰胺基”、“氨基甲酰胺基”和“氨基”上的取代基可以与相邻的氮原子一起形成含有可选择取代的N原子的杂环环），可选择取代的烷基、可选择取代的烯基、可选择取代的芳基或可选择取代的杂芳基）或其盐。
• NAPHTHYLIDINE DERIVATIVE HAVING HIV INTEGRASE INHIBITORY ACTIVITY
  申请人：Shionogi Co., Ltd.

  公开号：EP1714966A1

  公开（公告）日：2006-10-25

  [Problems to be Solved] To provide a novel compound having antiviral activity, especially inhibitory activity against HIV integrase, a pharmaceutical composition, especially anti-HIV drug, containing the same. [Means to Solve the Problem] A compound of the formula: (wherein: R1 is optionally substituted aralkyl; R2 and R3 are each independently hydrogen, optionally substituted alkyl, optionally substituted amino, optionally substituted alkenyl or optionally substituted alkoxy (provided that each substituent for "optionally substituted" is a noncyclic group); R4 is hydrogen, optionally substituted carboxy, optionally substituted formylamino, optionally substituted carbamoyl, optionally substituted amino (provided that a substituent on amino in "optionally substituted formylamino", "optionally substituted carbamoyl" and "optionally substituted amino" may form an optionally-substituted N-atom containing heterocyclic ring together with an adjacent N atom), optionally substituted alkyl, optionally substituted alkenyl, optionally substituted aryl, or optionally substituted heteroaryl) or a salt thereof.

  [有待解决的问题］ 提供一种具有抗病毒活性，特别是对HIV整合酶抑制活性的新型化合物，以及含有该化合物的药物组合物，特别是抗HIV药物。 [解决问题的方法］ 一种式的化合物： (其中： R1 是任选取代的芳烷基； R2和R3各自独立地为氢、任选取代的烷基、任选取代的氨基、任选取代的烯基或任选取代的烷氧基（条件是 "任选取代 "的每个取代基均为非环基团） R4 是氢、任选取代的羧基、任选取代的甲酰氨基、任选取代的氨基甲酰基、任选取代的氨基（但 "任选取代的甲酰氨基"、"任选取代的氨基甲酰基 "和 "任选取代的氨基 "中氨基上的取代基可与邻近的 N 原子一起形成任选取代的含 N 原子的杂环）、任选取代的烷基、任选取代的烯基、任选取代的芳基或任选取代的杂芳基）或其盐。
• HETEROCYCLIC COMPOUNDS HAVING HIV INTEGRASE INHIBITORY ACTIVITY
  申请人：SHIONOGI & CO., LTD.

  公开号：EP1541558B1

  公开（公告）日：2008-08-13